# Phase 2 Study With SNF472 in Calciphylaxis Patients

> **NCT02790073** · PHASE2 · COMPLETED · sponsor: **Sanifit Therapeutics S. A.** · enrollment: 14 (actual)

## Conditions studied

- Calciphylaxis
- Calcific Uremic Arteriolopathy

## Interventions

- **DRUG:** SNF472

## Key facts

- **NCT ID:** NCT02790073
- **Lead sponsor:** Sanifit Therapeutics S. A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-11-15
- **Final completion:** 2017-11-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02790073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02790073, "Phase 2 Study With SNF472 in Calciphylaxis Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02790073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*